Premium
PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA
Author(s) -
Lebel E.,
Jain M. D.,
Prica A.,
Kukreti V.,
Kridel R.,
Laister R. C.,
Meng L.,
Delabie J.,
Weiss J.,
Panzarella T.,
Crump M.,
Kuruvilla J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.97_2881
Subject(s) - medicine , salvage therapy , autologous stem cell transplantation , regimen , obinutuzumab , clinical endpoint , progressive disease , surgery , oncology , lymphoma , rituximab , chemotherapy , clinical trial
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom